How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,494 results for

Giant Cell Arteritis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

2. Giant cell arteritis

Giant cell arteritis Giant cell arteritis - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Giant cell arteritis Last reviewed: February 2019 Last updated: December 2018 Summary Giant cell arteritis (GCA) is a common form of vasculitis in people aged 50 years or older. The extracranial branches of the carotid artery are usually affected. Irreversible blindness is the most common serious consequence. Aortic aneurysms (...) and corticosteroid-sparing benefit in the treatment of GCA. Definition Giant cell arteritis (GCA) is a granulomatous vasculitis of large and medium-sized arteries. It primarily affects branches of the external carotid artery, and it is the most common form of systemic vasculitis in adults. GCA typically occurs in people 50 years of age or older and is more common in women. Symptoms of polymyalgia rheumatica are frequently present. The most common serious consequence of GCA is irreversible loss of vision due

2018 BMJ Best Practice

3. Giant cell arteritis

Giant cell arteritis Giant cell arteritis - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Giant cell arteritis Last reviewed: February 2019 Last updated: December 2018 Summary Giant cell arteritis (GCA) is a common form of vasculitis in people aged 50 years or older. The extracranial branches of the carotid artery are usually affected. Irreversible blindness is the most common serious consequence. Aortic aneurysms (...) and corticosteroid-sparing benefit in the treatment of GCA. Definition Giant cell arteritis (GCA) is a granulomatous vasculitis of large and medium-sized arteries. It primarily affects branches of the external carotid artery, and it is the most common form of systemic vasculitis in adults. GCA typically occurs in people 50 years of age or older and is more common in women. Symptoms of polymyalgia rheumatica are frequently present. The most common serious consequence of GCA is irreversible loss of vision due

2018 BMJ Best Practice

4. Magnetic resonance angiography in giant cell arteritis: results of a randomized controlled trial of tocilizumab in giant cell arteritis. (PubMed)

Magnetic resonance angiography in giant cell arteritis: results of a randomized controlled trial of tocilizumab in giant cell arteritis. To analyse magnetic resonance angiographic (MRA) vessel wall signals from a randomized controlled trial of tocilizumab (TCZ) to treat GCA.Participants were assigned in a 2:1 ratio to receive either TCZ + glucocorticoids (GCs) or placebo + GC infusions at 4-week intervals for 52 weeks. GCs were started at 1 mg/kg/day, then tapered to 0.1 mg/kg/day at week 12

2018 Rheumatology (Oxford, England)

5. Giant---cell arteritis---related mortality in France: A multiple---cause---of---death analysis Giant---cell arteritis---related mortality in France. (PubMed)

Giant---cell arteritis---related mortality in France: A multiple---cause---of---death analysis Giant---cell arteritis---related mortality in France. Giant-cell arteritis (GCA) is a large vessel vasculitis. Data regarding mortality are controversial. We describe the mortality data of the French death certificates for the period of 2005 to 2014.Using multiple-cause-of-death (MCOD) analysis, we calculated age-adjusted mortality rates for GCA, examined differences in mortality rates according

2018 Autoimmunity reviews

6. Ultrasound could help diagnose giant cell arteritis

Ultrasound could help diagnose giant cell arteritis Ultrasound could help diagnose giant cell arteritis Discover Portal Discover Portal Ultrasound could help diagnose giant cell arteritis Published on 14 February 2017 doi: Ultrasound may aid giant cell arteritis diagnosis in people referred from the community. It is less invasive than biopsy and might provide quicker results than a biopsy, but its role and place in the diagnostic pathway remain unclear. Giant cell arteritis is a disease (...) of medium to large sized arteries and can lead to a range of eye, brain and other complications. Sudden or gradual blindness is a real risk and anyone with suspected giant cell arteritis is referred to hospital for a biopsy and started on high dose steroids. This NIHR-funded study found that ultrasound correctly picks up more cases than biopsies, but also falsely identifies some people who do not have the condition. Biopsies falsely diagnose giant cell arteritis in fewer people without the condition

2019 NIHR Dissemination Centre

7. Ultrasound could help diagnose giant cell arteritis

Ultrasound could help diagnose giant cell arteritis Ultrasound could help diagnose giant cell arteritis Discover Portal Discover Portal Ultrasound could help diagnose giant cell arteritis Published on 14 February 2017 doi: Ultrasound may aid giant cell arteritis diagnosis in people referred from the community. It is less invasive than biopsy and might provide quicker results than a biopsy, but its role and place in the diagnostic pathway remain unclear. Giant cell arteritis is a disease (...) of medium to large sized arteries and can lead to a range of eye, brain and other complications. Sudden or gradual blindness is a real risk and anyone with suspected giant cell arteritis is referred to hospital for a biopsy and started on high dose steroids. This NIHR-funded study found that ultrasound correctly picks up more cases than biopsies, but also falsely identifies some people who do not have the condition. Biopsies falsely diagnose giant cell arteritis in fewer people without the condition

2018 NIHR Dissemination Centre

8. Tocilizumab for treating giant cell arteritis

Tocilizumab for treating giant cell arteritis T T ocilizumab for treating giant cell ocilizumab for treating giant cell arteritis arteritis T echnology appraisal guidance Published: 18 April 2018 nice.org.uk/guidance/ta518 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view of NICE, arrived at after careful consideration (...) to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. T ocilizumab for treating giant cell arteritis (TA518) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 21Contents Contents 1 Recommendations 4 2 Information about tocilizumab 5 3 Committee discussion 6 A new treatment option 6 Subgroups 6

2018 National Institute for Health and Clinical Excellence - Technology Appraisals

9. Combined bilateral ophthalmic artery occlusion & central retinal vein occlusion from presumed giant cell arteritis (PubMed)

Combined bilateral ophthalmic artery occlusion & central retinal vein occlusion from presumed giant cell arteritis To report on a severe case of presumed giant cell arteritis (GCA) presenting with partial and complete ophthalmic artery occlusion along with bilateral central retinal vein occlusions (CRVO).A 73-year-old female presented with bilateral complete vision loss of sudden onset. The patient also experienced a mild frontal headache prior to onset of vision loss. Fundus examination

Full Text available with Trip Pro

2018 American journal of ophthalmology case reports

10. The impact of temporal artery biopsy for the diagnosis of giant cell arteritis in clinical practice in a tertiary university hospital. (PubMed)

The impact of temporal artery biopsy for the diagnosis of giant cell arteritis in clinical practice in a tertiary university hospital. Temporal artery biopsy (TAB) is useful in assisting with giant cell arteritis (GCA) diagnosis but lacks sensitivity. The aim of our study was to assess the diagnostic impact of TAB histology in patients with suspected GCA on hospital admission.A prospectively maintained database was queried for all TABs performed between 1-1-2000 until 31-12-2017

Full Text available with Trip Pro

2019 PLoS ONE

11. Aspirin as adjunctive treatment for giant cell arteritis. (PubMed)

Aspirin as adjunctive treatment for giant cell arteritis. Giant cell arteritis (GCA) is a common inflammatory condition that affects medium and large-sized arteries and can cause sudden, permanent blindness. At present there is no alternative to early treatment with high-dose corticosteroids as the recommended standard management. Corticosteroid-induced side effects can develop and further disease-related ischaemic complications can still occur. Alternative and adjunctive therapies are sought (...) . Aspirin has been shown to have effects on the immune-mediated inflammation in GCA, hence it may reduce damage caused in the arterial wall.To assess the safety and effectiveness of low-dose aspirin, as an adjunctive, in the treatment of giant cell arteritis (GCA).We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (2013, Issue 12), Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to January 2014

Full Text available with Trip Pro

2014 Cochrane

12. Color duplex ultrasonography findings of temporal arteries in a case of giant cell arteritis: role in diagnosis and follow-up (PubMed)

Color duplex ultrasonography findings of temporal arteries in a case of giant cell arteritis: role in diagnosis and follow-up Giant cell arteritis (GCA) is a systemic autoimmune disease that affects medium- and large-sized arteries. The diagnostic gold standard is the temporal artery biopsy, but it has limited sensitivity and some difficulties in reproducibility. Color duplex ultrasonography is a noninvasive, reproducible, and inexpensive method for diagnosis of temporal arteries involvement (...) (temporal arteritis [TA]) in GCA with high sensitivity and specificity. We present the ultrasound findings at baseline and during follow-up in a case of TA in a patient with GCA.

Full Text available with Trip Pro

2017 Open access rheumatology : research and reviews

13. Giant cell arteritis, polymyalgia rheumatica, and late-onset rheumatoid arthritis: Can they be components of a single disease process in elderly patients? (PubMed)

Giant cell arteritis, polymyalgia rheumatica, and late-onset rheumatoid arthritis: Can they be components of a single disease process in elderly patients? To report two patients with giant cell arteritis (GCA) who developed rheumatoid arthritis (RA) and to review the literature in terms of coexistence of RA, GCA, and polymyalgia rheumatica (PMR).We conducted a comprehensive review of the English literature from 1980 to 2015 to analyze data on the coexistence of GCA and RA. The PubMed, Web (...) of Science, Proquest, and Ovid databases were searched for articles using the term RA combined with temporal arteritis, GCA, and PMR.We identified 17 other cases of coexistent GCA and RA reported in the English literature, together with our 2 cases (19 cases). They included 14 females and 5 males, with a mean age of 74.3 years (range: 57-84) at the time of GCA. The mean age at the time of RA diagnosis was 69.6 years (range 24-83). The average time elapsed between the onset of GCA and the development

Full Text available with Trip Pro

2017 European journal of rheumatology

14. Estimating the Cost of Illness of Giant Cell Arteritis in the United States (PubMed)

Estimating the Cost of Illness of Giant Cell Arteritis in the United States Giant cell arteritis (GCA) is a chronic vasculitis affecting approximately 230,000 Americans. Limited data exist on the healthcare resource utilization and costs attributable to GCA. The objective of this study was to estimate the cost of illness in patients with GCA in the US.A cohort of patients with a new GCA diagnosis was identified from a large US claims database between 1 January 2008 and 31 December 2012. Newly

Full Text available with Trip Pro

2017 Rheumatology and therapy

15. Increased Incidence of Giant Cell Arteritis in Urban Areas? (PubMed)

Increased Incidence of Giant Cell Arteritis in Urban Areas? 30647168 2019 03 02 0315-162X 46 3 2019 Mar The Journal of rheumatology J. Rheumatol. Increased Incidence of Giant Cell Arteritis in Urban Areas? 327-328 10.3899/jrheum.180714 Brekke Lene Kristin LK http://orcid.org/0000-0001-5599-2498 Hospital for Rheumatic Diseases, Haugesund, and Department of Clinical Science, University of Bergen, and Bergen Group of Epidemiology and Biomarkers in Rheumatic Disease (BEaBIRD), Department

Full Text available with Trip Pro

2019 Journal of Rheumatology

16. Efficacy of Methotrexate in Real-world Management of Giant Cell Arteritis: A Case-control Study. (PubMed)

Efficacy of Methotrexate in Real-world Management of Giant Cell Arteritis: A Case-control Study. To determine the effect of methotrexate (MTX) on relapse risk and glucocorticoid (GC) use in a large single-institution cohort of patients with giant cell arteritis (GCA).Patients diagnosed with GCA from 1998 to 2013 with confirmed evidence of temporal artery biopsy and/or radiographic evidence of large vessel vasculitis were identified. Each patient with GCA treated with adjunct MTX (case

2019 Journal of Rheumatology

17. The therapeutic potential of tuftsin-phosphorylcholine in giant cell arteritis. (PubMed)

The therapeutic potential of tuftsin-phosphorylcholine in giant cell arteritis. Tuftsin-PhosphorylCholine (TPC) is a novel bi-specific molecule which links tuftsin and phosphorylcholine. TPC has shown immunomodulatory activities in experimental mouse models of autoimmune diseases. We studied herein the effects of TPC ex vivo on both peripheral blood mononuclear cells (PBMCs) and temporal artery biopsies (TABs) obtained from patients with giant cell arteritis (GCA) and age-matched disease (...) controls. GCA is an immune-mediated disease affecting large vessels. Levels of 18 cytokines in supernatants, PBMC viability, T helper (Th) cell differentiation of PBMCs and gene expression in TABs were analyzed. Treatment ex vivo with TPC decreased the production of IL-1β, IL-2, IL-5, IL-6, IL-9, IL-12(p70), IL-13, IL-17A, IL-18, IL-21, IL-22, IL-23, IFNγ, TNFα, GM-CSF by CD3/CD28 activated PBMCs whereas it negligibly affected cell viability. It reduced Th1 and Th17 differentiation while did not impact

2019 Journal of Autoimmunity

18. Rate of Comorbidities in Giant Cell Arteritis: A Population-based Study

Rate of Comorbidities in Giant Cell Arteritis: A Population-based Study To compare the rate of occurrence of comorbidities, including severe infections, in a population-based cohort of patients with biopsy-proven giant cell arteritis (GCA) with a reference population in Southern Sweden.The study included a population-based cohort of biopsy-proven GCA cases diagnosed between 1998 and 2010 from the Skåne region in Southern Sweden (population: 1.2 million). For each patient, 4 reference subjects

Full Text available with Trip Pro

2017 EvidenceUpdates

19. Trial of Tocilizumab in Giant-Cell Arteritis. (PubMed)

Trial of Tocilizumab in Giant-Cell Arteritis. Giant-cell arteritis commonly relapses when glucocorticoids are tapered, and the prolonged use of glucocorticoids is associated with side effects. The effect of the interleukin-6 receptor alpha inhibitor tocilizumab on the rates of relapse during glucocorticoid tapering was studied in patients with giant-cell arteritis.In this 1-year trial, we randomly assigned 251 patients, in a 2:1:1:1 ratio, to receive subcutaneous tocilizumab (at a dose of 162 (...) that underwent the 26-week taper, and 25% of those in the placebo group that underwent the 52-week taper. Anterior ischemic optic neuropathy developed in one patient in the group that received tocilizumab every other week.Tocilizumab, received weekly or every other week, combined with a 26-week prednisone taper was superior to either 26-week or 52-week prednisone tapering plus placebo with regard to sustained glucocorticoid-free remission in patients with giant-cell arteritis. Longer follow-up is necessary

2017 NEJM

20. Giant cell arteritis and vascular disease-risk factors and outcomes: a cohort study using UK Clinical Practice Research Datalink

Giant cell arteritis and vascular disease-risk factors and outcomes: a cohort study using UK Clinical Practice Research Datalink To evaluate the associations between GCA and vascular diseases and other comorbidities in patients with GCA compared with non-vasculitis patients.Using the UK-based Clinical Practice Research Datalink we identified 9778 newly diagnosed GCA patients in 1990-2014, and up to 10 non-vasculitis patients randomly matched to each case on age, sex, practice and years

Full Text available with Trip Pro

2017 EvidenceUpdates

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>